Patient Support | TRYNGOLZA™ (olezarsen) Injection

We know how difficult it can be to live with familial chylomicronemia syndrome, but with Ionis Every Step™, your patient is not alone. The Patient Education Manager is your patient’s support for the services below throughout the TRYNGOLZA treatment journey.

The Patient Education Manager can:

Explain the process to get TRYNGOLZA to your patient

Answer questions about TRYNGOLZA and provide support for your patient*

Teach patients how to inject TRYNGOLZA

Training is available in person, over the phone, or virtually, based on the patient’s preference

Offer services and resources, such as nutrition support, to help support patient outcomes

*Patient Education Managers do not provide clinical recommendations and will refer patients back to their HCP as necessary.

For more information about Ionis Every Step, call 1-844-789-8744 (Monday to Friday, 8 AM to 8 PM ET)

See how to get patients started on TRYNGOLZA

Important safety information

CONTRAINDICATIONS

TRYNGOLZA is contraindicated in patients with a history of serious hypersensitivity to TRYNGOLZA or any of the excipients in TRYNGOLZA. Hypersensitivity reactions requiring medical treatment have occurred.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Hypersensitivity reactions (including symptoms of bronchospasm, diffuse erythema, facial swelling, urticaria, chills, and myalgias) have been reported in patients treated with TRYNGOLZA. Advise patients on the signs and symptoms of hypersensitivity reactions and instruct patients to promptly seek medical attention and discontinue use of TRYNGOLZA if hypersensitivity reactions occur.

ADVERSE REACTIONS

Most common adverse reactions (incidence >5% of TRYNGOLZA-treated patients and >3% higher frequency than placebo) were injection site reactions, decreased platelet count, and arthralgia.

Please see full Prescribing Information for TRYNGOLZA.

Indication

TRYNGOLZA (olezarsen) is indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS).

Indication

TRYNGOLZA (olezarsen) is indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS).

Important safety information

CONTRAINDICATIONS

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

ADVERSE REACTIONS

Most common adverse reactions (incidence >5% of TRYNGOLZA-treated patients and >3% higher frequency than placebo) were injection site reactions, decreased platelet count, and arthralgia.

Please see full Prescribing Information for TRYNGOLZA.

References: 1. TRYNGOLZA™. Prescribing information. Ionis Pharmaceuticals; 2024. 2. Data on file. Human factors assessment. Ionis Pharmaceuticals; 2024. 3. Davidson M, Stevenson M, Hsieh A, et al. The burden of familial chylomicronemia syndrome: results from the global IN-FOCUS study. J Clin Lipidol. 2018;12(4):89‌8-90‌7.e2. 4. Gaudet D, Brisson D, Tremblay K, et al. Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med. 2014;3‌71(23):22‌00-22‌06. 5. Ginsberg HN, Packard CJ, Chapman MJ, et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society. Eur Heart J. 2021;42(47‌):47‌91-480‌6. 6. Moulin P, Dufour R, Averna M, et al. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): expert panel recommendations and proposal of an "FCS score". Atherosclerosis. 2018;2‌75:265-‌272. 7. D'Erasmo L, Di Costanzo A, Cassandra F, et al. Spectrum of mutations and long-term clinical outcomes in genetic chylomicronemia syndromes. Arterioscler Thromb Vasc Biol. 2019;‌39(12):25‌31-25‌41. 8. Belhassen M, Van Ganse E, Nolin M, et al. 10-year comparative follow-up of familial versus multifactorial chylomicronemia syndromes. J Clin Endocrinol Metab. 202‌1;106(3):e13‌32-e1‌342. 9. Gaudet D, Blom D, Bruckert E, et al. Acute pancreatitis is highly prevalent and complications can be fatal in patients with familial chylomicronemia: results from a survey of lipidologist. J Clin Lipidol. 201‌6;10(3):68‌0-68‌1. National Lipid Association 2016 Scientific Sessions abstract 136. 10. Nawaz H, Koutroumpakis E, Easler J, et al. Elevated serum triglycerides are independently associated with persistent organ failure in acute pancreatitis. Am J Gastroenterol. 201‌5;110‌(10):149‌7-15‌03. 11. Shemesh E, Zafrir B. Hypertriglyceridemia-related pancreatitis in patients with type 2 diabetes: links and risks. Diabetes Metab Syndr Obes. 201‌9;12:2‌041-20‌52. 12. Stroes ESG, Alexander VJ, Karwatowska-Prokopczuk E, et al; Balance Investigators. Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome. N Engl J Med. 2024;390‌(19):1‌781-1‌792. 13. Stroes ESG, Alexander VJ, Karwatowska-Prokopczuk E, et al; Balance Investigators. Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome. N Engl J Med. 2024;3‌90(19)(supplementary appendix):178‌1-17‌92. 14. Data on file. REF-01848. Ionis Pharmaceuticals; 2024. 15. Data on file. REF-01852. Ionis Pharmaceuticals; 2024. 16. Data on file. REF-01850. Ionis Pharmaceuticals; 2024. 17. Data on file. Balance clinical study report. Ionis Pharmaceuticals; 2024.

Access and support

The Patient Education Manager can:

Indication

Important safety information

CONTRAINDICATIONS

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

ADVERSE REACTIONS